These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
994 related articles for article (PubMed ID: 30710469)
41. Antimicrobial Susceptibility Testing for Polymyxins: Challenges, Issues, and Recommendations. Ezadi F; Ardebili A; Mirnejad R J Clin Microbiol; 2019 Apr; 57(4):. PubMed ID: 30541939 [TBL] [Abstract][Full Text] [Related]
42. Colistin and Polymyxin B Dosage Regimens against Acinetobacter baumannii: Differences in Activity and the Emergence of Resistance. Cheah SE; Li J; Tsuji BT; Forrest A; Bulitta JB; Nation RL Antimicrob Agents Chemother; 2016 Jul; 60(7):3921-33. PubMed ID: 27067324 [TBL] [Abstract][Full Text] [Related]
43. Optimizing use of colistin and polymyxin B in the critically ill. Nation RL; Li J Semin Respir Crit Care Med; 2007 Dec; 28(6):604-14. PubMed ID: 18095224 [TBL] [Abstract][Full Text] [Related]
44. Personalizing Polymyxin B Dosing Using an Adaptive Feedback Control Algorithm. Lakota EA; Landersdorfer CB; Nation RL; Li J; Kaye KS; Rao GG; Forrest A Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760144 [TBL] [Abstract][Full Text] [Related]
46. Multidrug-resistant Gram-negative infections: the use of colistin. Michalopoulos AS; Karatza DC Expert Rev Anti Infect Ther; 2010 Sep; 8(9):1009-17. PubMed ID: 20818945 [TBL] [Abstract][Full Text] [Related]
47. Comparative study of polymyxin B and colistin sulfate in the treatment of severe comorbid patients infected with CR-GNB. Wang J; Shah BK; Zhao J; Xiong J; Wang C; Xie S BMC Infect Dis; 2023 May; 23(1):351. PubMed ID: 37231342 [TBL] [Abstract][Full Text] [Related]
48. History, Chemistry and Antibacterial Spectrum. Velkov T; Thompson PE; Azad MAK; Roberts KD; Bergen PJ Adv Exp Med Biol; 2019; 1145():15-36. PubMed ID: 31364069 [TBL] [Abstract][Full Text] [Related]
49. Predictors of polymyxin B treatment failure in Gram-negative healthcare-associated infections among critically ill patients. Ismail B; Shafei MN; Harun A; Ali S; Omar M; Deris ZZ J Microbiol Immunol Infect; 2018 Dec; 51(6):763-769. PubMed ID: 28716359 [TBL] [Abstract][Full Text] [Related]
50. Critical Role of Position 10 Residue in the Polymyxin Antimicrobial Activity. Patil NA; Ma W; Jiang X; He X; Yu HH; Wickremasinghe H; Wang J; Thompson PE; Velkov T; Roberts KD; Li J J Med Chem; 2023 Feb; 66(4):2865-2876. PubMed ID: 36745479 [TBL] [Abstract][Full Text] [Related]
51. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. Phe K; Lee Y; McDaneld PM; Prasad N; Yin T; Figueroa DA; Musick WL; Cottreau JM; Hu M; Tam VH Antimicrob Agents Chemother; 2014 May; 58(5):2740-6. PubMed ID: 24566187 [TBL] [Abstract][Full Text] [Related]
52. [Comparison of disc diffusion, E-test, and broth microdilution methods for the determination of resistance to colistin, polymyxin B, and tigecycline in multi-resistant Acinetobacter baumannii isolates]. Akin FE; Bayram A; Balci I Mikrobiyol Bul; 2010 Apr; 44(2):203-10. PubMed ID: 20549954 [TBL] [Abstract][Full Text] [Related]
53. Clinical and Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing Position Statements on Polymyxin B and Colistin Clinical Breakpoints. Satlin MJ; Lewis JS; Weinstein MP; Patel J; Humphries RM; Kahlmeter G; Giske CG; Turnidge J Clin Infect Dis; 2020 Dec; 71(9):e523-e529. PubMed ID: 32052041 [TBL] [Abstract][Full Text] [Related]
54. Quality control guidelines for testing gram-negative control strains with polymyxin B and colistin (polymyxin E) by standardized methods. Jones RN; Anderegg TR; Swenson JM; J Clin Microbiol; 2005 Feb; 43(2):925-7. PubMed ID: 15695708 [TBL] [Abstract][Full Text] [Related]
55. Polymyxin Susceptibility Testing and Breakpoint Setting. Turnidge J; Sei K; Mouton J Adv Exp Med Biol; 2019; 1145():117-132. PubMed ID: 31364075 [TBL] [Abstract][Full Text] [Related]
56. Nephrotoxicity in Patients with or without Cystic Fibrosis Treated with Polymyxin B Compared to Colistin. Crass RL; Rutter WC; Burgess DR; Martin CA; Burgess DS Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167560 [TBL] [Abstract][Full Text] [Related]
57. Optimal Empiric Polymyxin B Treatment of Patients Infected with Gram-Negative Organisms Detected Using a Blood Antimicrobial Surveillance Network in China. Wu X; Huang C; Wang H; Ji J; Ying C; Xiao Y Drug Des Devel Ther; 2021; 15():2593-2603. PubMed ID: 34168431 [TBL] [Abstract][Full Text] [Related]
58. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Lim LM; Ly N; Anderson D; Yang JC; Macander L; Jarkowski A; Forrest A; Bulitta JB; Tsuji BT Pharmacotherapy; 2010 Dec; 30(12):1279-91. PubMed ID: 21114395 [TBL] [Abstract][Full Text] [Related]
59. Parenteral polymyxin B use in patients with multidrug-resistant gram-negative bacteremia and urinary tract infections: a retrospective case series. Pastewski AA; Caruso P; Parris AR; Dizon R; Kopec R; Sharma S; Mayer S; Ghitan M; Chapnick EK Ann Pharmacother; 2008 Sep; 42(9):1177-87. PubMed ID: 18664609 [TBL] [Abstract][Full Text] [Related]
60. Colistin and Polymyxin B Susceptibility Testing for Carbapenem-Resistant and Chew KL; La MV; Lin RTP; Teo JWP J Clin Microbiol; 2017 Sep; 55(9):2609-2616. PubMed ID: 28592552 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]